Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.30 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27532989 | 0.90 | MTNR1A (0.53) | MTNR1AAIMP2ALDH1A1KDM4EKMT2A | |
| SCHEMBL5336888 | 0.88 | MTNR1A (0.56) | MTNR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL5342354 | 0.87 | MTNR1A (0.55) | MTNR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL5339473 | 0.87 | MTNR1A (0.55) | MTNR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL5229686 | 0.85 | MTNR1A (0.78) | MTNR1AHPGDALDH1A1KDM4EKMT2A | |
| SCHEMBL5345036 | 0.80 | MTNR1A (0.48) | MTNR1AHPGDALDH1A1KMT2AITGB3 | |
| SCHEMBL5340002 | 0.79 | MTNR1A (0.47) | MTNR1AKMT2ATRPV1ITGB3ITGA2B | |
| SCHEMBL27532937 | 0.77 | MTNR1A (0.53) | MTNR1AAIMP2ALDH1A1KDM4EKMT2A | |
| SCHEMBL5231199 | 0.69 | MTNR1A (0.75) | MTNR1AKDM4EKMT2AHSD17B10 | |
| SCHEMBL5334595 | 0.68 | MTNR1A (0.70) | MTNR1ATRPV1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885ADRA2A 562/4885ADRA2B 1008/4885 |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885ADRA2A 100/4885ADRA2B 263/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885ADRA2A 562/4885ADRA2B 1008/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | MTNR1A 409/4885ADRA2A 94/4885ADRA2B 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.